Skip to main content

Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer.

Publication ,  Journal Article
Duda, DG; Willett, CG; Ancukiewicz, M; di Tomaso, E; Shah, M; Czito, BG; Bentley, R; Poleski, M; Lauwers, GY; Carroll, M; Tyler, D; Mantyh, C ...
Published in: Oncologist
2010

We explored plasma and urinary concentrations of two members of the vascular endothelial growth factor (VEGF) family and their receptors as potential response and toxicity biomarkers of bevacizumab with neoadjuvant chemoradiation in patients with localized rectal cancer. The concentrations of VEGF, placental growth factor (PlGF), soluble VEGF receptor 1 (sVEGFR-1), and sVEGFR-2 were measured in plasma and urine at baseline and during treatment. Pretreatment values and changes over time were analyzed as potential biomarkers of pathological response to treatment as well as for acute toxicity in patients with locally advanced rectal cancer treated prospectively in 2002-2008 with neoadjuvant bevacizumab, 5-fluorouracil, radiation therapy, and surgery in a phase I/II trial. Of all biomarkers, pretreatment plasma sVEGFR-1-an endogenous blocker of VEGF and PlGF, and a factor linked with "vascular normalization"-was associated with both primary tumor regression and the development of adverse events after neoadjuvant bevacizumab and chemoradiation. Based on the findings in this exploratory study, we propose that plasma sVEGFR-1 should be further studied as a potential biomarker to stratify patients in future studies of bevacizumab and/or cytotoxics in the neoadjuvant setting.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Oncologist

DOI

EISSN

1549-490X

Publication Date

2010

Volume

15

Issue

6

Start / End Page

577 / 583

Location

England

Related Subject Headings

  • Young Adult
  • Vascular Endothelial Growth Factor Receptor-1
  • Treatment Outcome
  • Rectal Neoplasms
  • Oncology & Carcinogenesis
  • Neoadjuvant Therapy
  • Humans
  • Fluorouracil
  • Biomarkers, Tumor
  • Bevacizumab
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Duda, D. G., Willett, C. G., Ancukiewicz, M., di Tomaso, E., Shah, M., Czito, B. G., … Jain, R. K. (2010). Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist, 15(6), 577–583. https://doi.org/10.1634/theoncologist.2010-0029
Duda, Dan G., Christopher G. Willett, Marek Ancukiewicz, Emmanuelle di Tomaso, Mira Shah, Brian G. Czito, Rex Bentley, et al. “Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer.Oncologist 15, no. 6 (2010): 577–83. https://doi.org/10.1634/theoncologist.2010-0029.
Duda DG, Willett CG, Ancukiewicz M, di Tomaso E, Shah M, Czito BG, et al. Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist. 2010;15(6):577–83.
Duda, Dan G., et al. “Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer.Oncologist, vol. 15, no. 6, 2010, pp. 577–83. Pubmed, doi:10.1634/theoncologist.2010-0029.
Duda DG, Willett CG, Ancukiewicz M, di Tomaso E, Shah M, Czito BG, Bentley R, Poleski M, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito P, Clark JW, Jain RK. Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist. 2010;15(6):577–583.

Published In

Oncologist

DOI

EISSN

1549-490X

Publication Date

2010

Volume

15

Issue

6

Start / End Page

577 / 583

Location

England

Related Subject Headings

  • Young Adult
  • Vascular Endothelial Growth Factor Receptor-1
  • Treatment Outcome
  • Rectal Neoplasms
  • Oncology & Carcinogenesis
  • Neoadjuvant Therapy
  • Humans
  • Fluorouracil
  • Biomarkers, Tumor
  • Bevacizumab